In particular, deletions of XPO7 occurred in a significant percentage of samples obtained from different tumor types, including prostate adenocarcinomas (PRAD), colon adenocarcinomas (COAD), or liver hepatocellular carcinomas (LIHC), among others (Fig. 7A). This evidence concerns the gene XPO7 and colon adenocarcinoma.